Takeda Pharmaceutical Yönetim
Yönetim kriter kontrolleri 2/4
Takeda Pharmaceutical CEO'su Christophe Weber, Jun2014 tarihinde atandı, in görev süresi 10.42 yıldır. in toplam yıllık tazminatı ¥ 2.08B olup, şirket hissesi ve opsiyonları dahil olmak üzere 15.2% maaş ve 84.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.05% ine doğrudan sahiptir ve bu hisseler ¥ 3.38B değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 7.1 yıl ve 8.4 yıldır.
Anahtar bilgiler
Christophe Weber
İcra Kurulu Başkanı
JP¥2.1b
Toplam tazminat
CEO maaş yüzdesi | 15.2% |
CEO görev süresi | 10.4yrs |
CEO sahipliği | 0.05% |
Yönetim ortalama görev süresi | 7.1yrs |
Yönetim Kurulu ortalama görev süresi | 8.4yrs |
Son yönetim güncellemeleri
Recent updates
Results: Takeda Pharmaceutical Company Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Nov 04Takeda Pharmaceutical (TSE:4502) Is Increasing Its Dividend To ¥98.00
Sep 24Why Investors Shouldn't Be Surprised By Takeda Pharmaceutical Company Limited's (TSE:4502) P/E
Sep 20Takeda Pharmaceutical's (TSE:4502) Upcoming Dividend Will Be Larger Than Last Year's
Aug 08Earnings Beat: Takeda Pharmaceutical Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Aug 02Takeda Pharmaceutical (TSE:4502) Is Increasing Its Dividend To ¥98.00
Jul 25Takeda Pharmaceutical's (TSE:4502) Upcoming Dividend Will Be Larger Than Last Year's
Jul 11Takeda Pharmaceutical Company Limited (TSE:4502) Yearly Results: Here's What Analysts Are Forecasting For This Year
Jun 30Takeda Pharmaceutical (TSE:4502) Takes On Some Risk With Its Use Of Debt
Jun 11Some Investors May Be Willing To Look Past Takeda Pharmaceutical's (TSE:4502) Soft Earnings
May 21Takeda Pharmaceutical Company Limited Just Recorded A 6.0% EPS Beat: Here's What Analysts Are Forecasting Next
May 12Takeda Pharmaceutical (TSE:4502) Is Due To Pay A Dividend Of ¥94.00
Mar 28Takeda Pharmaceutical (TSE:4502) Has Announced A Dividend Of ¥94.00
Mar 13Takeda Pharmaceutical (TSE:4502) Will Pay A Dividend Of ¥94.00
Feb 26CEO Tazminat Analizi
Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
---|---|---|---|
Sep 30 2024 | n/a | n/a | JP¥290b |
Jun 30 2024 | n/a | n/a | JP¥150b |
Mar 31 2024 | JP¥2b | JP¥317m | JP¥144b |
Dec 31 2023 | n/a | n/a | JP¥178b |
Sep 30 2023 | n/a | n/a | JP¥192b |
Jun 30 2023 | n/a | n/a | JP¥301b |
Mar 31 2023 | JP¥2b | JP¥295m | JP¥317b |
Dec 31 2022 | n/a | n/a | JP¥275b |
Sep 30 2022 | n/a | n/a | JP¥213b |
Jun 30 2022 | n/a | n/a | JP¥197b |
Mar 31 2022 | JP¥2b | JP¥281m | JP¥230b |
Dec 31 2021 | n/a | n/a | JP¥439b |
Sep 30 2021 | n/a | n/a | JP¥473b |
Jun 30 2021 | n/a | n/a | JP¥431b |
Mar 31 2021 | JP¥2b | JP¥267m | JP¥376b |
Dec 31 2020 | n/a | n/a | JP¥181b |
Sep 30 2020 | n/a | n/a | JP¥56b |
Jun 30 2020 | n/a | n/a | JP¥120b |
Mar 31 2020 | JP¥2b | JP¥273m | JP¥44b |
Dec 31 2019 | n/a | n/a | JP¥13b |
Sep 30 2019 | n/a | n/a | JP¥83b |
Jun 30 2019 | n/a | n/a | JP¥64b |
Mar 31 2019 | JP¥2b | JP¥269m | JP¥135b |
Dec 31 2018 | n/a | n/a | JP¥110b |
Sep 30 2018 | n/a | n/a | JP¥141b |
Jun 30 2018 | n/a | n/a | JP¥120b |
Mar 31 2018 | JP¥1b | JP¥254m | JP¥187b |
Tazminat ve Piyasa: Christophe 'nin toplam tazminatı ($USD 13.75M ), JP pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.40M ).
Tazminat ve Kazançlar: Christophe 'in maaşı son bir yılda %20'den fazla arttı.
CEO
Christophe Weber (58 yo)
10.4yrs
Görev süresi
JP¥2,083,000,000
Tazminat
Mr. Christophe Weber has been the President and Chief Executive Officer of Takeda Pharmaceutical Company Limited since June 27, 2014 and April 2015 respectively and served as its Chief Operating Officer fr...
Liderlik Ekibi
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
President | 10.4yrs | JP¥2.08b | 0.050% ¥ 3.4b | |
Chair of Management Board | no data | Veri yok | Veri yok | |
CFO & Director | less than a year | Veri yok | 0.00083% ¥ 56.6m | |
Member of Management Board | no data | Veri yok | Veri yok | |
Member of Management Board and Head of R&D Global Science & Biomedical Policy | no data | Veri yok | Veri yok | |
Chief Accounting Officer & Corporate Controller | no data | Veri yok | Veri yok | |
Senior Vice President of Corporate Finance & Controlling Department | 11.7yrs | Veri yok | Veri yok | |
Chief Data & Technology Officer | 2.8yrs | Veri yok | Veri yok | |
Global Head of Investor Relations & Global Finance | 4.2yrs | Veri yok | Veri yok | |
Global General Counsel | 10.1yrs | Veri yok | Veri yok | |
Chief Ethics & Compliance Officer | 10.1yrs | Veri yok | Veri yok | |
Chief Human Resources Officer | 3.8yrs | Veri yok | Veri yok |
7.1yrs
Ortalama Görev Süresi
51.5yo
Ortalama Yaş
Deneyimli Yönetim: 4502 'un yönetim ekibi deneyimli ve deneyimlidir ( 7.1 yıldır).
Yönetim Kurulu Üyeleri
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
President | 10.4yrs | JP¥2.08b | 0.050% ¥ 3.4b | |
CFO & Director | no data | Veri yok | 0.00083% ¥ 56.6m | |
President of Research & Development and Representative Director | 9.4yrs | JP¥972.00m | 0.0087% ¥ 595.1m | |
Independent External Director | 2.4yrs | JP¥32.00m | Veri yok | |
Independent External Director | 5.8yrs | JP¥44.00m | 0.00026% ¥ 17.7m | |
Independent External Director | 8.4yrs | JP¥49.00m | 0.00016% ¥ 10.9m | |
Independent External Director | 8.4yrs | JP¥40.00m | 0.00079% ¥ 53.8m | |
Independent External Director | 5.8yrs | JP¥44.00m | 0.000070% ¥ 4.8m | |
Independent External Director | 5.4yrs | JP¥38.00m | Veri yok | |
Independent External Director | 8.4yrs | JP¥46.00m | Veri yok | |
Independent External Chair | 3.4yrs | JP¥43.00m | 0.000020% ¥ 1.4m | |
Independent External Director | 8.4yrs | JP¥43.00m | 0.00063% ¥ 42.9m |
8.4yrs
Ortalama Görev Süresi
66.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: 4502 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.4 yıldır).